Intelligent Bio Solutions Faces Delisting Concerns
Ticker: INBS · Form: 8-K · Filed: Dec 16, 2025 · CIK: 1725430
Sentiment: bearish
Topics: delisting, compliance, listing-standards
TL;DR
Intelligent Bio Solutions might be delisted, check exchange status.
AI Summary
Intelligent Bio Solutions Inc. filed an 8-K on December 16, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, formerly known as GBS Inc., is incorporated in Delaware and has its principal executive offices in New York, NY.
Why It Matters
This filing indicates potential issues with the company's compliance with stock exchange listing requirements, which could impact its trading status and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's continued trading on an exchange.
Key Players & Entities
- Intelligent Bio Solutions Inc. (company) — Registrant
- GBS Inc. (company) — Former company name
- December 15, 2025 (date) — Date of earliest event reported
- December 16, 2025 (date) — Filing date
- New York, NY (location) — Principal executive offices
FAQ
What specific listing rule has Intelligent Bio Solutions Inc. failed to satisfy?
The filing does not specify the exact listing rule that has not been satisfied, only that a notice of delisting or failure to satisfy a continued listing rule has been issued.
What is the earliest event date reported in this 8-K filing?
The earliest event date reported is December 15, 2025.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted on December 16, 2025.
What were the previous names of Intelligent Bio Solutions Inc.?
The company was formerly known as GBS Inc. and prior to that, Glucose Biosensor Systems (Greater China) Holdings, Inc.
Where are the principal executive offices of Intelligent Bio Solutions Inc. located?
The principal executive offices are located at 135 West 41st Street, 5th Floor, New York, NY 10036.
Filing Stats: 814 words · 3 min read · ~3 pages · Grade level 12.9 · Accepted 2025-12-16 17:15:25
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value INBS The Nasdaq Stock Mar
- $1.00 — or the Company's common stock was below $1.00 per share for the last 30 consecutive b
Filing Documents
- form8-k.htm (8-K) — 38KB
- 0001493152-25-028003.txt ( ) — 203KB
- inbs-20251215.xsd (EX-101.SCH) — 3KB
- inbs-20251215_lab.xml (EX-101.LAB) — 33KB
- inbs-20251215_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 16, 2025 INTELLIGENT BIO SOLUTIONS INC. By: /s/ Spiro Sakiris Name: Spiro Sakiris Title: Chief Financial Officer